TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04827823

Intervention type: OTHER
Intervention: Retrospective evaluation of amalgam and composite restorations
Description: Multi-surface restorations that were performed by dental students and that are in function for the last five years will be clinically evaluated with mirrors and probes according to the modified USPHS criteria.

Intervention type: OTHER
Intervention: Retrospective evaluation of amalgam and composite restorations
Description: Multi-surface restorations that were performed by dental students and that are in function for the last five years will be clinically evaluated with mirrors and probes according to the modified USPHS criteria.
Study: NCT03432143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Reviewers
Description: Intervention manuscripts will be reviewed by both a trained community member and scientific reviewers. Community reviewers will follow each journal's instructions regarding electronic access to manuscripts, use of drop-down menus and free-text boxes to address specific aspects of the review, and completion within the time frame specified by the journal.The journal editorial team will use all reviews to make decisions about acceptance, revision, or rejection of manuscripts.
Study: NCT02502149

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Description: As per arm description

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Description: As per arm description
Study: NCT02508337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XG-102
Description: Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
Study: NCT02459444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powerbreathe
Description: Respiratory equipment for physiotherapy, offering to load muscles inspiratory

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: This was contemplated cinesioterapia unloaded, muscle stretching, coughing technique, sedestração and ambulation if the participant was fit.
Study: NCT04494191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flibanserin 100 MG [Addyi]
Description: One tablet contains 100 mg Flibanserin
Study: NCT04580875

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive surgery (laparoscopy and laparoscopic-assisted procedures) in both diagnosis and treatment of penetrating abdominal trauma in Children

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive surgery (laparoscopy and laparoscopic-assisted procedures) in both diagnosis and treatment of penetrating abdominal trauma in Children
Study: NCT02689713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole (topical)
Description: The voriconazole (Vfend®-IV 200mg) will be applied topically to one of two skin graft sites at a concentration of 150 micromolar. Dialysates will be collected over 12 hours post-skin graft/voriconazole application for analysis in the lab of OLAM concentrations.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Sterile Water Placebo Group
Description: Sterile water will be applied topically to the other of the two skin graft sites. Dialysates will be collected over 12 hours post-skin graft/sterile water application for analysis in the lab of OLAM concentrations.
Study: NCT02290782

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Description: The surgeon and radiation oncologist should choose the largest possible suitable applicator in order to ensure that the highest possible dose is delivered to the tumor bed tissue. A dose of 20 Gy at the surface of the applicator (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 20-50 minutes, depending on the size of the applicator.~To minimize radiation dependent side effects the skin-applicator surface distance should be more than 5 mm.
Study: NCT02863588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: seropositive for Toxoplasma gondii
Description: blood sample
Study: NCT02152930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: 1000 mg of omega-3 fatty acid ethylesters, 2 times daily, for 4 weeks, followed by 12 weeks of supervised exercise therapy in combination with 2 times daily omega-3 fatty acid supplementation.
Study: NCT04440761

Intervention type: OTHER
Intervention: Observation only
Description: Observation only
Study: NCT02736669

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Energy Reduction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy Reduction
Study: NCT01379989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Lipoxomal Doxorubicin (PLD)
Description: PLD 30 mg/m² i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Lipoxomal Doxorubicin (PLD)
Description: PLD 30 mg/m² i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: trabectedin 1.1 mg/m2 3-hour i.v. infusion on Day 1 every 3 weeks. The use of central venous access is strongly recommended.
Study: NCT02392312

Intervention type: DRUG
Intervention: ATF-Fresenius S
Description: intravenous
Study: NCT02901184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Treatment with Spironolactone tablets on top of standard care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Standard care does not involve Spironolactone
Study: NCT04547829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated recombinant human granulocyte-colony stimulating factor
Description: The dosage was determined according to the patient's weight, 100 UG / kg each time; The method of administration: subcutaneous injection; The time of administration: 24-48 hours after the end of chemotherapy, once in each chemotherapy cycle.
Study: NCT02821546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's solution
Description: Standard fluid hydration with Lactated Ringer's solution is calculated based on Holiday Segar's equation Aggressive hydration with Lactated Ringer's solution is defined as administration of 150 ml/hour of fluid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactated Ringer's solution
Description: Standard fluid hydration with Lactated Ringer's solution is calculated based on Holiday Segar's equation Aggressive hydration with Lactated Ringer's solution is defined as administration of 150 ml/hour of fluid
Study: NCT02881866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Study: NCT02459444

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiotherapy
Description: This was contemplated cinesioterapia unloaded, muscle stretching, coughing technique, sedestração and ambulation if the participant was fit.
Study: NCT01582399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASKP1240
Description: intravenous(IV) infusion and subcutaneous (SC)
Study: NCT01615965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tumor marker detection in lymph nodes
Description: tumor marker detection in lymph nodes by quantitative PCR
Study: NCT02127021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norzyme® 40000 IU
Description: A kind of pancreatic enzyme supplement containing lipase: 40,000 FIP, amylase: 25,000 FIP, and protease: 1,500 FIP Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.
Study: NCT00128336

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle: diet and exercise intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle: diet and exercise intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle: diet and exercise intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle: diet and exercise intervention
Study: NCT03000075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for risankizumab
Description: Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
Study: NCT02508337

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
Study: NCT03202082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing
Description: Neuropsychological testing evaluates various aspects of a participants cognitive ability as well as mood.
Study: NCT01880892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cricopharyngeal myotomy
Description: Endoscopic laser cricopharyngeal myotomy is one of the standard treatments for Zenker's Diverticulum. It takes about 30 minutes and at our institution requires a one night of observation in the hospital.
Study: NCT03000075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for risankizumab
Description: Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
Study: NCT01871519

Intervention type: DEVICE
Group type: OTHER
Intervention: Balloon kyphoplasty
Description: The devices to be used in this study are intended for percutaneous balloon kyphoplasty (BKP) and consist of the Kyphon® bone access needles and cannulae, inflatable bone tamps, curettes, polymethyl methacrylate bone cement (PMMA) bone cements, and bone filler devices.
Study: NCT01706523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STX209 (arbaclofen)
Description: Long-term, daily, orally-administered STX209
Study: NCT02219334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NoseFrida
Description: The NoseFrida has four components, the collection container, an interchangeable filter, flexible tubing and a mouth piece. The end of the collection devise is placed on the patient's nostril, a tight seal is made via the vacuum created from suctioning of the mouth piece and secretions are easily aspirated. This device disassembles for quick disinfecting and cleaning.
Study: NCT02035527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given daily PO in the a.m.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV over 1 hour following Docetaxel administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV 1 hour prior to cisplatin administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative Studies
Description: Correlative studies will be performed at the following time points. A total of three biopsies (blood and tumor samples) will be obtained in consenting patients.Pre-treatment biopsy to establish diagnosis and baseline data, Research biopsy obtained at the end of a two week period of sorafenib monotherapy just prior to administration of cycle1 with cisplatin and docetaxel, Research biopsy obtained at the end of two chemotherapy cycles.
Study: NCT02544659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pamidronate disodium
Description: the patients will be administered pamidronate disodium 1 mg/kg, IV, QD, for 3 days, and every 3 month (up to month 6)
Study: NCT01988675

Intervention type: RADIATION
Intervention: Whole Brain Irradiation

Intervention type: RADIATION
Intervention: Partial Brain Irradiation

Intervention type: BEHAVIORAL
Intervention: Neuropsychological Testing

Intervention type: BEHAVIORAL
Intervention: Neuropsychological Testing

Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionnaire
Study: NCT04347174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suspension of heat killed (autoclaved) Mycobacterium w
Description: Patients will be randomized to receive either Mycobacterium w in combination with standard care as per hospital practice or standard care alone in COVID-19 as per hospital practice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients will continue to receive standard therapy as per hospital practice till considered requisite by the treating physician
Study: NCT03093558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECA/Kardia
Description: Use of the ECA and Kardia daily for 30 days.
Study: NCT03844802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Dry needling and exercise
Description: Deep dry needling will be applied bilaterally in the locus of active or latent myofascial trigger points of several neck shoulder muscles (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius). The presence of active or latent myofascial trigger points will be assessed according to the diagnostic procedures described by Travell and Simons. The dry needling intervention technique will be the fast in-fast out Hong technique, with a minimum of 3 to 6 local twitch responses to be elicited.~Patients will perform a home based therapeutic neck exercises program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Distal Dry needling and exercise
Description: Patients in this group will undergo deep dry needling at a remote spot from the locus of the myofascial trigger point. As a result no local twitch response should be elicited. As in the previous group, dry needling will be carried out in the same assessed muscles (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius) with active or latent myofascial trigger points, according to the diagnostic procedures described by Travell and Simons. The intervention technique chosen for these participants will be to insert the needle in a location in the same muscle, but far away (at least 1 to 1.5 cm) from the location of the myofascial trigger point. Likewise, the needle will be inserted without the intention to evoke local twitch responses. Therefore, the entry and exit of the needle will be performed in a slower fashion.~Patients will perform a home based therapeutic neck exercises program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham dry needling and exercise
Description: Patients in this group will undergo sham-placebo dry needling. For that purpose, placebo dry needling will be carried out in the same muscles previously described (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius) with active or latent myofascial trigger points. The intervention technique will be carried out in the locus of the trigger point but using placebo needles. For this placebo group, a simulation needle procedure using a Dong Bang placebo needle, similar to the Streitberger needle, will be used. The placebo needles evoke mechanical stimulation without piercing the skin; hence, patients experience a pressure sensation similar to that of a real needle.~Patients will perform a home based therapeutic neck exercises program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Patients will perform a home based therapeutic neck exercises program.
Study: NCT02222246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone (Standardized, weight-based dosing)
Description: Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate (Standardized, weight-based dosing)
Description: Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone (Patient Specific dosing)
Description: Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate (Patient Specific dosing)
Description: Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
Study: NCT02064231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test A
Description: Coloplast Test A is a new ostomy appliance developed by Coloplast A/S

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test B
Description: Coloplast Test B is a newly developed ostomy appliance developed by Coloplast A/S

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Own product
Description: Own product is tested to get baseline results. Own product can be any 2-piece product that is commercially available. The manufactures can be Coloplast, Hollister, Convatec, Dansac, B. Braun and others.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Own product
Description: Own product is tested to get baseline results. Own product can be any 2-piece product that is commercially available. The manufactures can be Coloplast, Hollister, Convatec, Dansac, B. Braun and others.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test C
Description: Coloplast Test C is a new ostomy appliance developed by Coloplast A/S

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test D
Description: Coloplast Test D is a new ostomy appliance developed by Coloplast A/S
Study: NCT00673868

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV Specific Cytotoxic T Lymphocytes
Description: CMV Specific Cytotoxic T Lymphocytes will be infused between days 30 and 40 post-transplant at a dose ranging from 2- 5 x e5 cells/kg.
Study: NCT00923299

Intervention type: DRUG
Group type: OTHER
Intervention: cetuximab
Description: Cetuximab at the initial dose of 400 mg/m² (J1S1) as a 2-hour infusion and then at the 250 mg/m² dose as a 1-hour infusion in subsequent weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: trastuzumab
Description: Two dose levels of trastuzumab will be evaluated for Phase 1:~* Level 1: a loading dose of 3 mg/kg as a 90-minute intravenous infusion at J1S1 and then 1.5 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations;~* Level 2: a loading dose of 4 mg/kg as a 90-minute intravenous infusion at J1S1 and then 2 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations.
Study: NCT04066101

Intervention type: GENETIC
Intervention: high caries risk
Description: DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit Genotyping for a variant was carried out on a Roche Applied Science LightCycler® 480 (Roche Diagnostics GmbH, Mannheim, Germany) with real-time polymerase reaction of Taqman

Intervention type: GENETIC
Intervention: high caries risk
Description: DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit Genotyping for a variant was carried out on a Roche Applied Science LightCycler® 480 (Roche Diagnostics GmbH, Mannheim, Germany) with real-time polymerase reaction of Taqman

Intervention type: OTHER
Intervention: caries activity
Description: Dental caries lesions of all patient scored as initial, moderate or advanced caries~Initial lesion; clinically detectable lesion Moderate; visible signs of enamel breakdown Advanced; enamel was fully cavitaed

Intervention type: OTHER
Intervention: caries activity
Description: Dental caries lesions of all patient scored as initial, moderate or advanced caries~Initial lesion; clinically detectable lesion Moderate; visible signs of enamel breakdown Advanced; enamel was fully cavitaed
Study: NCT00540735

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Study: NCT03910439

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 800 mg intravenous (IV) over 60 minutes (+/- 20 minutes) on days 1 and 15 of each 28-day cycle

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: 5 gray (Gy) per fraction will be delivered on 5 consecutive treatment days for a total dose 25 Gy
Study: NCT03955016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Rehabilitation program consisting of 2 weeks inpatient (supervised training 5 times per week), 2 weeks outpatient (supervised sessions 3 times per week) and 11 weeks home-based exercise training (weekly phone call).~During the inpatient phase, patients will receive on top of the supervised training sessions a consultation of the dietitian, PH psychologist, social worker and specialized nurse. During the ambulatory rehabilitation phase patients will have 2 session with the occupational therapist.~Every supervised training session contains:~1. Interval training on a cyclo-ergometer~2. Strength training of the upper and lower extremities~3. Guided walks
Study: NCT00939068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: Subjects start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continued to one month after delivery.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: engineered HB vaccine
Description: All the newborns in control group are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20 ug respectively at age of 0, 1 and 6 months.
Study: NCT03506724

Intervention type: DRUG
Group type: OTHER
Intervention: Nifedipine
Description: Nifedipine 10mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given and institution specific protocol will be performed.

Intervention type: DRUG
Group type: OTHER
Intervention: Labetalol
Description: Labetalol 20mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 40mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 80mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, then another medication will be chosen based on institution specific protocol.